Blog
RSS FeedPosted by Michael Wonder on 05 Feb 2024
Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma
2 February 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 04 Feb 2024
Ruxolitinib phosphate for the treatment of patients with non-segmental vitiligo
31 January 2024 - The Department of Health and Social Care has asked NICE to produce guidance on using ruxolitinib ...
Posted by Michael Wonder on 02 Feb 2024
Fenfluramine hydrochloride for the treatment of patients with Lennox-Gastaut seizures
31 January 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 02 Feb 2024
Prioritising pills for the people: getting new medicines on schedule a complex process, by New Zealand Doctor
2 February 2024 - The funding of pharmaceuticals is an issue that often makes its way into news headlines. PHARMAC Director, ...
Posted by Michael Wonder on 01 Feb 2024
Significant additional benefit of mavacamten in hypertrophic obstructive cardiomyopathy
1 February 2024 - In a dossier assessment in 2023, an additional benefit could not yet be proven due to unclear ...
Posted by Michael Wonder on 01 Feb 2024
Ivosidenib for the treatment of patients with advanced IDH1 R132 mutation positive cholangiocarcinoma after one or more systemic treatments
31 January 2024 - NICE has published final evidence-based recommendations on the use of ivosidenib (Tibsovo) for the treatment of ...
Posted by Michael Wonder on 31 Jan 2024
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
31 January 2024 - NICE has published evidence-based recommendations on the use of loncastuximab tesirine (Zynlonta) for the treatment of ...
Posted by Michael Wonder on 30 Jan 2024
Treosulphan in combination with fludarabine phosphate before allogeneic stem cell transplantation for patients aged 1 month to 17 years with non-malignant diseases
30 January 2024 - NICE is unable to make a recommendation on the use of treosulphan (Trecondi) in combination with fludarabine ...
Posted by Michael Wonder on 29 Jan 2024
Updates to the HTA Review: options paper for Consultation 2 published
25 January 2024 - The Options paper for Consultation 2 is now available on the Office of Health Technology Assessment consultation ...
Posted by Michael Wonder on 26 Jan 2024
Outcomes from the December 2023 PBAC intracycle meeting
25 January 2024 - The outcomes from the December 2023 PBAC intracycle meeting are now available. ...
Posted by Michael Wonder on 25 Jan 2024
PHARMAC joins global health technology assessment network
25 January 2024 - PHARMAC has joined the International Network of Agencies for Health Technology Assessment (INAHTA) - a network ...
Posted by Michael Wonder on 23 Jan 2024
Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease
18 January 2024 - NICE has published additional draft guidance on the use of remdesivir and the combination of tixagevimab ...
Posted by Michael Wonder on 22 Jan 2024
PHARMAC publishes agenda for next month's PTAC meeting
18 January 2024 - Surprise, surprise yet another underwhelming agenda. ...
Posted by Michael Wonder on 22 Jan 2024
NICE issues draft guidance for use of remdesivir and also for tixagevimab-cilgavimab for treatment of COVID-19
18 January 2024 - Draft guidance for public consultation has been published by NICE. ...
Posted by Michael Wonder on 19 Jan 2024
300 people to benefit from new treatment for advanced breast cancer recommended by NICE following price deal
19 January 2024 - Around 300 people are set to benefit following NICE’s recommendation of talazoparib tosylate for treating a type ...